卡巴马西平的多态性和药理学评估
Alberto Sá Filho1, Jose Luis Rodrigues Martins1, Rafael Fernandes Costa1
1Graduate Program in Pharmaceutical Sciences, Evangelical University of Goiás, Anapolis 75083-515, GO, Brazil.
International journal of molecular sciences
|September 28, 2024
概括
卡巴马西平配方 (CBZ-F) 通过GABAergic机制调解,通过增强睡眠和减少小鼠发作,显示出作为抗药的潜力. 为了临床应用,需要进行进一步的研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
背景情况:
- 卡巴马泽 (CBZ) 是一种已知抗药物 (AED).
- 了解碳胺多态体及其对药物特性的影响对于配方开发至关重要.
- 像托皮拉 (TOP),氧卡巴塞 (OXC) 和西 (DZP) 这样的现有的抗体抑制剂作为基准.
研究的目的:
- 在小鼠中研究卡巴马西平 (CBZ) 和一种新型卡巴马西平配方 (CBZ-F) 的细胞保护性,中枢神经系统抑制性和抗性.
- 在临床前模型中将CBZ-F与CBZ,TOP,OXC和DZP进行比较.
- 阐明GABAergic机制在观察到的药理作用中的作用.
主要方法:
- 在体外评估神经元活力的评估.
- 在体内对小鼠进行的研究包括开放场,旋转杆,巴比图拉剂诱导睡眠和烯甲醇 (PTZ) 诱导的试验.
- 药理学评估使用弗卢马塞尼尔预处理来评估GABAergic参与.
主要成果:
- 而CBZ,CBZ-F和TOP则表现出轻微的细胞保护作用.
- CBZ-F和参考AED增强了巴比图拉特诱导的睡眠和改变了运动活动.
- CBZ-F和参考AED减轻了PTZ诱导的发作,而flumazenil阻断了效果,表明GABAergic调解.
结论:
- 卡巴马泽配方 (CBZ-F) 显示出有前途的抗和中枢神经系统抑制性质.
- 观察到的效应很可能通过GABAergic通路进行介导.
- CBZ-F需要进一步进行临床前研究,以确定其在治疗中的潜在临床效用.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
102
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
102
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Nonlinear Pharmacokinetics: Causes of Nonlinearity
144
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
144
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
289
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
289
Antiepileptic Drugs: GABAergic Pathway Potentiators
341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341


